"brutons agammaglobulinemi" or "x-bundet agammaglobulinemi" or bruton Treff i utvalgte kilder: [Skjul boksen]
  1. bmj-bestpractice
    -
    https://bestpractice.bmj.com/topics/en-gb/312/emergingtxs
    /
    ... nlm.nih.gov/pubmed/25925619?tool=bestpractice.com Bruton kinase inhibitors Ibrutinib has been shown to have ... Advani RH, Buggy JJ, Sharman JP, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant ...
  2. bmj-bestpractice
    -
    https://bestpractice.bmj.com/topics/en-us/312/emergingtxs
    /
    ... nlm.nih.gov/pubmed/25925619?tool=bestpractice.com Bruton kinase inhibitors Ibrutinib has been shown to have ... Advani RH, Buggy JJ, Sharman JP, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant ...
  3. nokc-helsebiblioteket-collection
    -
    https://www.helsebiblioteket.no/.../Agammaglobulinemi(1)
    /
    ... beskrevet. Insidens : Ca 1/ 200 000 nyfødte gutter. X-bundet agammaglobulinemi (XLA); Brutons agammaglobulinemi Bakgrunn Mutasjon i BTK genet som koder for Brutons tyrosin kinase. Resulterer i manglende B-lymfocyttmodning (manglende, ...
  4. bmj-bestpractice
    -
    https://bestpractice.bmj.com/topics/en-gb/897/pdf/897.pdf
    /
    ... the B-cell tumour growth in concert with Bruton's tyrosine kinase (BTK) . [ 9] An MYD88-independent ... as monotherapy and in combination. Ibrutinib, an oral Bruton's tyrosine kinase (BTK) inhibitor, is approved in ...
  5. bmj-bestpractice
    -
    https://bestpractice.bmj.com/topics/en-us/897/pdf/897.pdf
    /
    ... the B-cell tumor growth in concert with Bruton tyrosine kinase (BTK) . [ 8] An MYD88-independent Sp1 ... as monotherapy and in combination. Ibrutinib, an oral Bruton tyrosine kinase (BTK) inhibitor, is approved for first- ...
  6. bmj-bestpractice
    -
    https://bestpractice.bmj.com/topics/en-gb/1058/pdf/1058.pdf
    /
    ... isotypes with profoundly decreased or absent B cells • Bruton's tyrosine kinase (BTK) deficiency (mutation on the ... and Ig production; leads to X-linked agammaglobulinaemia/Bruton's disease) • Mu heavy-chain deficiency • Lambda-5 ...
  7. bmj-bestpractice
    -
    https://bestpractice.bmj.com/topics/en-us/1058/pdf/1058.pdf
    /
    ... isotypes with profoundly decreased or absent B cells • Bruton tyrosine kinase (BTK) deficiency (mutation on the BTK ... and Ig production; leads to X-linked agammaglobulinemia/Bruton disease) • Mu heavy-chain deficiency • Lambda-5 deficiency • ...
  8. bmj-bestpractice
    -
    https://bestpractice.bmj.com/topics/en-gb/897/treatment-algorithm
    /
    ... 420 mg orally once daily Ibrutinib, an oral Bruton's tyrosine kinase (BTK) inhibitor, is approved in ... 420 mg orally once daily Ibrutinib, an oral Bruton's tyrosine kinase (BTK) inhibitor, is approved in ...
  9. bmj-bestpractice
    -
    https://bestpractice.bmj.com/topics/en-us/897/treatment-algorithm
    /
    ... 420 mg orally once daily Ibrutinib, an oral Bruton tyrosine kinase (BTK) inhibitor, is approved for first- ... 420 mg orally once daily Ibrutinib, an oral Bruton tyrosine kinase (BTK) inhibitor, is approved for first- ...
  10. bmj-bestpractice
    -
    https://bestpractice.bmj.com/topics/en-gb/312/pdf/312.pdf
    /
    ... refractory NHL and chronic lymphocytic leukaemia (CLL) . [ 130] Bruton kinase inhibitors Ibrutinib has been shown to have ... given promising early results. Acalabrutinib, a second-generation bruton kinase inhibitor, has been granted FDA accelerated approval ...
første · forrige · 1 · 2 · 3 · 4 · 5 · neste · siste